Coatings having an elastic primer layer

• US 9,056,155 B1
• Filed: 05/29/2007
• Issued: 06/16/2015
• Est. Priority Date: 05/29/2007
• Status: Active Grant

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Kleiner, Lothar W., Tang, Yiwen, Trollsas, Mikael O., Hossainy, Syed F. A., Prabhu, Santosh
• Primary Examiner(s): Switzer, Juliet
• Assistant Examiner(s): HELM, CARALYNNE E
• Application Number:
  US11/807,833
• Time in Patent Office: 2,940 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: C08G 63/6856 Dicarboxylic acids and dihydroxy compounds
• CPC Class Codes: C08L 67/02 Polyesters derived from dicarboxylic acids and dihydroxy compounds C08L67/06 takes precedence
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: C09D 167/02 Polyesters derived from dicarboxylic acids and dihydroxy compounds C09D167/06 takes precedence

Abstract

Provided herein is a coating an elastic primer layer and the method of making and using the same.

Claims

1. An implantable medical device comprising a coating, the coating comprising:

an elastic primer layer comprising a polymer formed on a surface of an implantable medical device, and the polymer being poly(butylene succinate); and

a matrix layer or a drug depot layer on top of the primer layer;

wherein the matrix layer or the drug depot layer comprises at least one bioactive agent.

2. The implantable medical device of claim 1, wherein the primer layer further comprises an elastic polycaprolactone (PCL) polymer.

3. The implantable medical device of claim 1, wherein the primer layer further comprises an elastic polyester polymer.

4. The implantable medical device of claim 1, wherein the drug depot layer is free of polymers.

5. The implantable medical device of claim 1, which is a stent.

6. The implantable medical device of claim 2, which is a stent.

7. The implantable medical device of claim 3, which is a stent.

8. The implantable medical device of claim 1, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl(4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxyl)ethyl-rapamycin (everolimus), 40-O-(3-hydroxyl)propyl-rapamycin, 40-O-[2-(2-hydroxyl)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), zotarolimus, γ

-hiridun, clobetasol, mometasone, dexamethasone, dexamethasone acetate, pimecrolimus, imatinib mesylate, midostaurin, and combinations of these.

9. The stent of claim 5, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl(4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxyl)ethyl-rapamycin (everolimus), 40-O-(3-hydroxyl)propyl-rapamycin, 40-O-[2-(2-hydroxyl)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), zotarolimus, γ

-hiridun, clobetasol, mometasone, dexamethasone, dexamethasone acetate, pimecrolimus, imatinib mesylate, midostaurin, and combinations of these.

10. The implantable medical device of claim 1, wherein the polymer of the primer layer has a molecular weight above the entanglement molecular weight.